Penumbra

Executive Summary

Penumbra is a global medical device company specializing in innovative solutions for neurovascular and peripheral vascular conditions, including acute ischemic stroke and venous thrombus management. Founded in 2004 and headquartered in Alzenau, Germany, the company has built a reputation for developing technologies that address critical unmet needs in vascular intervention. With a focus on patient outcomes and physician usability, Penumbra's product portfolio includes catheter-based systems for thrombectomy and embolization. Despite being a private entity with limited public financial data, the company is well-established in the interventional radiology and neurology markets. Its continued investment in R&D and clinical evidence positions it for sustained growth, though competitive pressures from larger players remain a factor. Penumbra's ability to navigate regulatory approvals and expand into new geographies will be key to its long-term success.

Upcoming Catalysts (preview)

• Q3 2026FDA Approval of Next-Generation Thrombectomy Device75% success
• Q4 2026Positive 12-Month Data from Peripheral Vascular Clinical Trial60% success
• Q1 2027European CE Mark Expansion for New Stroke Indication80% success